Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yang Yin Fu Zheng Jie Du therapy in HBV-HCC induced anemia
NCT05088733Phase 1Unknown
- Sponsor
- Beijing Ditan Hospital
- Start
- Jul 2020
- Primary completion
- Jun 2023
- Modality
- HM (Herbal Medicine), Combination therapy
- Countries
- 1
01
Overview
Phase 1 trial of Yangyin Fuzheng Jiedu Prescription in hepatocellular carcinoma (HCC) (2 arms), sponsored by Beijing Ditan Hospital. Primary endpoint: Survival rate at 1 year. Status: unknown.
02
Drugs
Yangyin Fuzheng Jiedu Prescription
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05088733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05088733.